BIIB
Price
$177.08
Change
+$0.75 (+0.43%)
Updated
Dec 26 closing price
Capitalization
25.98B
33 days until earnings call
Intraday BUY SELL Signals
DSNKY
Price
$21.84
Change
+$0.42 (+1.96%)
Updated
Dec 26 closing price
Capitalization
40.69B
Intraday BUY SELL Signals
Interact to see
Advertisement

BIIB vs DSNKY

Header iconBIIB vs DSNKY Comparison
Open Charts BIIB vs DSNKYBanner chart's image
Biogen
Price$177.08
Change+$0.75 (+0.43%)
Volume$687.4K
Capitalization25.98B
Daiichi Sankyo
Price$21.84
Change+$0.42 (+1.96%)
Volume$656.07K
Capitalization40.69B
BIIB vs DSNKY Comparison Chart in %
BIIB
Daily Signal:
Gain/Loss:
DSNKY
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
BIIB vs. DSNKY commentary
Dec 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a Buy and DSNKY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 27, 2025
Stock price -- (BIIB: $177.08 vs. DSNKY: $21.84)
Brand notoriety: BIIB: Notable vs. DSNKY: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: BIIB: 32% vs. DSNKY: 215%
Market capitalization -- BIIB: $25.98B vs. DSNKY: $40.69B
BIIB [@Pharmaceuticals: Major] is valued at $25.98B. DSNKY’s [@Pharmaceuticals: Major] market capitalization is $40.69B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $964.61B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $104.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIIB’s FA Score shows that 1 FA rating(s) are green whileDSNKY’s FA Score has 2 green FA rating(s).

  • BIIB’s FA Score: 1 green, 4 red.
  • DSNKY’s FA Score: 2 green, 3 red.
According to our system of comparison, both BIIB and DSNKY are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIIB’s TA Score shows that 4 TA indicator(s) are bullish while DSNKY’s TA Score has 4 bullish TA indicator(s).

  • BIIB’s TA Score: 4 bullish, 4 bearish.
  • DSNKY’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, BIIB is a better buy in the short-term than DSNKY.

Price Growth

BIIB (@Pharmaceuticals: Major) experienced а +1.30% price change this week, while DSNKY (@Pharmaceuticals: Major) price change was +3.26% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.12%. For the same industry, the average monthly price growth was +1.24%, and the average quarterly price growth was +14.71%.

Reported Earning Dates

BIIB is expected to report earnings on Jan 29, 2026.

Industries' Descriptions

@Pharmaceuticals: Major (+1.12% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DSNKY($40.7B) has a higher market cap than BIIB($26B). DSNKY has higher P/E ratio than BIIB: DSNKY (22.80) vs BIIB (16.14). BIIB YTD gains are higher at: 15.799 vs. DSNKY (-19.971). DSNKY has higher annual earnings (EBITDA): 400B vs. BIIB (2.93B). DSNKY has more cash in the bank: 594B vs. BIIB (3.96B). BIIB has less debt than DSNKY: BIIB (6.59B) vs DSNKY (201B). DSNKY has higher revenues than BIIB: DSNKY (1.98T) vs BIIB (10.1B).
BIIBDSNKYBIIB / DSNKY
Capitalization26B40.7B64%
EBITDA2.93B400B1%
Gain YTD15.799-19.971-79%
P/E Ratio16.1422.8071%
Revenue10.1B1.98T1%
Total Cash3.96B594B1%
Total Debt6.59B201B3%
FUNDAMENTALS RATINGS
BIIB vs DSNKY: Fundamental Ratings
BIIB
DSNKY
OUTLOOK RATING
1..100
1954
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
31
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
743
PRICE GROWTH RATING
1..100
4378
P/E GROWTH RATING
1..100
2685
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DSNKY's Valuation (31) in the null industry is somewhat better than the same rating for BIIB (92) in the Biotechnology industry. This means that DSNKY’s stock grew somewhat faster than BIIB’s over the last 12 months.

DSNKY's Profit vs Risk Rating (100) in the null industry is in the same range as BIIB (100) in the Biotechnology industry. This means that DSNKY’s stock grew similarly to BIIB’s over the last 12 months.

DSNKY's SMR Rating (3) in the null industry is significantly better than the same rating for BIIB (74) in the Biotechnology industry. This means that DSNKY’s stock grew significantly faster than BIIB’s over the last 12 months.

BIIB's Price Growth Rating (43) in the Biotechnology industry is somewhat better than the same rating for DSNKY (78) in the null industry. This means that BIIB’s stock grew somewhat faster than DSNKY’s over the last 12 months.

BIIB's P/E Growth Rating (26) in the Biotechnology industry is somewhat better than the same rating for DSNKY (85) in the null industry. This means that BIIB’s stock grew somewhat faster than DSNKY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIIBDSNKY
RSI
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
63%
Bullish Trend 2 days ago
69%
Momentum
ODDS (%)
Bullish Trend 2 days ago
60%
Bullish Trend 2 days ago
70%
MACD
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
57%
Bullish Trend 2 days ago
68%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
59%
Bearish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 2 days ago
57%
Bullish Trend 2 days ago
70%
Declines
ODDS (%)
Bearish Trend 19 days ago
69%
Bearish Trend 6 days ago
73%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
48%
Bearish Trend 4 days ago
72%
Aroon
ODDS (%)
Bullish Trend 2 days ago
41%
Bearish Trend 2 days ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
BIIB
Daily Signal:
Gain/Loss:
DSNKY
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CULP3.500.12
+3.55%
Culp
HOVNP20.45N/A
N/A
Hovnanian Enterprises
SFM79.60-0.08
-0.10%
Sprouts Farmers Market
NEOG7.13-0.01
-0.14%
Neogen Corp
CADL6.01-0.07
-1.15%
Candel Therapeutics

BIIB and

Correlation & Price change

A.I.dvisor indicates that over the last year, BIIB has been closely correlated with PFE. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if BIIB jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIIB
1D Price
Change %
BIIB100%
+0.43%
PFE - BIIB
69%
Closely correlated
+0.24%
AMGN - BIIB
59%
Loosely correlated
-0.31%
MRK - BIIB
57%
Loosely correlated
+0.31%
BMY - BIIB
54%
Loosely correlated
-0.13%
ABBV - BIIB
52%
Loosely correlated
+0.04%
More

DSNKY and

Correlation & Price change

A.I.dvisor indicates that over the last year, DSNKY has been loosely correlated with CHGCY. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if DSNKY jumps, then CHGCY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DSNKY
1D Price
Change %
DSNKY100%
+1.96%
CHGCY - DSNKY
38%
Loosely correlated
+1.20%
OTSKY - DSNKY
37%
Loosely correlated
+0.65%
DSKYF - DSNKY
34%
Loosely correlated
+3.44%
BIIB - DSNKY
23%
Poorly correlated
+0.43%
ALPMY - DSNKY
21%
Poorly correlated
-0.07%
More